| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash used in financing activities | -281,786 | -281,788 |
| Net increase in cash, cash equivalents and restricted cash | -22,658 | 90,906 |
| Cash and cash equivalents at beginning of period | 126,250 | - |
| Cash and cash equivalents at end of period | 103,592 | - |
Coherus Oncology, Inc. (CHRS)
Coherus Oncology, Inc. (CHRS)